大脑粉样性血管病变影响神经纤维状的负担和认知能力
Dana Godrich1, Jeremy Pasteris1,2, Eden R Martin1,2
1Dr. John T Macdonald Foundation Department of Human Genetics, Miller School of Medicine, University of Miami, Miami, FL 33136, USA.
Brain communications
|November 25, 2024
概括
大脑粉样血管病变通过在阿尔茨海默病中恶化神经纤维细胞退化导致认知障碍. 这项研究证实了大型临床队列中的联系,强调了粉样血管病变在阿尔茨海默氏症病理学中的作用.
科学领域:
- 神经病理学神经病理学
- 神经退行性疾病 神经退行性疾病
- 认知障碍 认知障碍是一种认知障碍.
背景情况:
- 大脑粉样蛋白血管病变 (CAA) 通常与阿尔茨海默病 (AD) 病理学同时发生,包括粉样蛋白斑块和神经纤维状结.
- 在阿尔茨海默氏症中,CAA,神经纤维细胞退化和认知衰退之间的精确相互作用仍然不完全理解.
- 以前的研究表明神经纤维细胞退化介导CAA和认知障碍之间的关联.
研究的目的:
- 复制和扩展关于神经纤维细胞退化在CAA和认知障碍之间的关联中介作用的发现.
- 为了研究CAA对认知障碍的影响,在一大批临床依据的尸体解剖患者中.
- 检查APOE e4基因型对这些关系的影响.
主要方法:
- 来自国家阿尔茨海默氏症协调中心的4915名尸检参与者的分析,其中60%被诊断为痴呆症.
- 神经病理病变的常规测量,包括大脑粉样血管病变和神经纤维状结.
- 用于评估认知障碍的纵向认知数据,包括逻辑回归和调解分析在内的统计分析,包括APOE e4状态.
主要成果:
- 在大脑粉样血管病变和神经性斑块之间观察到显著的统计相互作用,影响神经纤维状的负担.
- 调解分析证实,大脑粉样血管病变与认知障碍有关,主要是通过修改神经纤维状结对认知的影响.
- 将APOE e4状态纳入扩展调解模型产生了类似的结果,加强了主要发现.
结论:
- 大脑粉样血管病变在神经纤维细胞退化的发展和影响中起着重要作用.
- 这些发现强调了脑粉样血管病变在阿尔茨海默病病理学背景下对认知障碍的贡献的重要性.
- 了解这种相互作用对于开发针对阿尔茨海默病的向治疗策略至关重要.
更多相关视频
相关概念视频
01:26Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
01:22Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
03:03Amyloid Fibrils
9.2K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.2K
01:30Dementia
96
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
96
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
98
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
98